Patel Chem Specialities Ltd logo

Patel Chem Specialities IPO

  • Status: Closed
  • RHP:
  • ₹ 262,400 / 3200 shares

    Minimum Investment

Patel Chem Specialities IPO Details

  • Open Date

    25 Jul 2025

  • Close Date

    29 Jul 2025

  • Listing Date

    01 Aug 2025

  • IPO Price Range

    ₹ 82 to ₹84

  • IPO Size

    ₹ 55.83 Cr

  • Listing Exchange

    BSE SME

Open Free Demat Account

+91

By proceeding, you agree to all T&C*

hero_form

Patel Chem Specialities IPO Subscription Status

Last Updated: 29 July 2025 6:19 PM by 5paisa

Patel Chem Specialities Limited (PCSL) is launching a ₹55.83 crore IPO. The company manufactures and exports pharmaceutical excipients and specialty chemicals used in pharma, food, cosmetics, and industrial applications. With facilities in Ahmedabad and Himmatnagar, PCSL maintains international standards like US-DMF and GMP. Its 7,000 sq. yard plant produces over 7,200 MT annually. PCSL exports globally to East Asia, Europe, North America, and more, offering high-quality, certified chemical solutions.

Established in: 2008
Managing Director: Mr. Bhupesh Patel

 

Peers

Accent Microcell Limited
Sigachi Industries Limited
 

Patel Chem Specialities Objectives

1. Funding capital expenditure of the company
2. General corporate purposes
 

Patel Chem Specialities IPO Size

Types Size
Total IPO Size ₹55.83 Cr
Offer For Sale -
Fresh Issue ₹55.83 Cr

 

Patel Chem Specialities IPO Lot Size

Application Lots Shares Amount
Retail (Min) 2 3200 262,400
Retail (Max) 2 3200 262,400
S-HNI (Min) 3 4800 393,600
S-HNI (Max) 7 11,200 918,400
B-HNI (Min) 8 12,800 10,49,600

Patel Chem Specialities IPO Reservation

Investors Category Subscription (times) Shares Offered Shares bid for Total Amount (Cr.)*
QIB 105.27 13,29,600 13,99,71,200 1,175.76
NII (HNI) 236.62 9,98,400 23,62,44,800 1,984.46
Individual Investors (IND category bidding for 2 Lots)     173.03 23,31,200 40,33,69,600 3,388.30
Total** 167.32 46,59,200 77,95,85,600 6,548.52

 

*The "Shares Offered" and "Total Amount" are calculated using the upper limit of the issue price range.
**Shares allocated to anchor investors (or market makers) are excluded from the total number of shares offered.

Profit and Loss

Balance Sheet

Particulars (in Rs. Crores) FY23 FY24 FY25
Revenue 69.75 82.72 105.55
EBITDA 5.83 12.02 15.80
PAT 2.89 7.66 10.57
Particulars (in Rs. Crores) FY23 FY24 FY25
Total Assets 37.08 46.97 65.31
Share Capital 1.00 1.00 17.87
Total Borrowings 11.79 15.46 14.85
Particulars (in Rs. Crores) FY23 FY24 FY25
Net Cash Generated From / (used in) operating activities 1.97 6.08 1.90
Net Cash Generated From / (used in) investing activities -3.27 -5.94 -7.20
Net Cash Generated From / (used in) financing activities 0.81 0.32 5.42
Net Increase (Decrease) In Cash And Cash Equivalents -0.50 0.46 0.12


Strengths

1. Over a decade of operations in specialty chemicals, since 2008.
2. Stable customer and supplier base ensuring consistent operations.
3. Diversified clientele across textiles, paints, rubber, and construction sectors.
4. In-house R&D and quality control help maintain industry innovation.

Weaknesses

1. High client concentration increases reliance on a few large customers.
2. Regulatory approvals necessary across agencies, risking project delays.
3. Forex exposure from exports may impact profitability due to volatility.
4. Dependence on top-tier approvals could stall growth through regulatory changes.

Opportunities

1. Expansion in industrial sectors like paints and construction fuels growth.
2. Diversified end-markets reduce dependency on pharmaceutical clients.
3. In-house innovation positions the company to develop differentiated products.
4. New export markets can drive top-line growth, despite foreign exchange risks.

Threats

1. Stringent licensing requirements may delay operations or affect volumes.
2. Currency fluctuations pose risk to margins on global sales.
3. Dependence on limited large customers can be destabilising if lost.
3. Heightened competition in specialty chemicals may pressure pricing.

1. Consistent revenue growth from ₹69.75 Cr (FY23) to ₹105.55 Cr (FY25).
2. Serves diversified sectors like textiles, paints, rubber, construction, and pharmaceuticals.
3. In-house R&D and global quality certifications ensure product reliability and innovation.
4. IPO funds to support capital expenditure and strengthen overall corporate operations.

1. Specialty chemicals sector in India is projected to grow steadily with rising global demand.
2. Patel Chem operates in excipients and industrial additives—both seeing strong multi-sector usage growth.
3. Government push for local manufacturing supports chemical firms with export focus like Patel Chem.
4. Expanding global footprint positions the company well for long-term, innovation-led growth in niche segments.

Upcoming IPOs

View all IPOs
  • Companies
  • Type
  • Opening On

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

FAQs

Patel Chem Specialities IPO opens from July 25, 2025 to July 29, 2025.

The size of Patel Chem Specialities IPO is ₹55.83 Cr.

The price band of Patel Chem Specialities IPO is fixed at ₹82 to ₹84 per share.

To apply for Patel Chem Specialities IPO, follow the steps given below:

●    Login to your 5paisa account and select the issue in the current IPO section    
●    Enter the number of lots and the price at which you wish to apply for the Patel Chem Specialities  IPO.    
●    Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.    

You will receive a mandate notification to block funds in your UPI app.
 

The minimum lot size of Patel Chem Specialities IPO is of 2 lots consisting of 3,200 shares and the investment required is ₹262,400.

The share allotment date of Patel Chem Specialities IPO is July 30, 2025

The Patel Chem Specialities IPO will likely be listed on August 1, 2025.

Cumulative Capital Private Limited is the book running lead manager for Patel Chem Specialities IPO.

Patel Chem Specialities plans to utilise the raised capital from the IPO for:

  • Funding capital expenditure of the company
  • General corporate purposes